Skip to main
HAE

Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics (HAE) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Haemonetics is a leading medical products and solutions company that operates in three segments - plasma, blood center, and hospital. With a shifting focus towards its plasma and hospital segments, the company is well-positioned for growth due to its innovative products and solutions, strong market presence, and potential for sustained sales growth through new products and M&A opportunities. Despite facing some challenges in its blood center segment, Haemonetics is expected to continue improving its profitability, making it an attractive investment opportunity.

Bears say

Haemonetics is a company that operates under three segments, including plasma, blood center, and hospital. However, its blood center segment faces higher competition, which could limit its revenue growth potential. In contrast, the company's plasma segment has a strong growth potential, driven by the demand for its disposable blood component collection and processing products. Additionally, the hospital segment's growth is also expected to be supported by acquisitions and exposure to fast-growing Medical Device therapies. However, the overall negative outlook for the company is due to the expected decline in sales for its vascular closure devices and a revised guidance for hospital sales.

Haemonetics (HAE) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Haemonetics (HAE) Forecast

Analysts have given Haemonetics (HAE) a Buy based on their latest research and market trends.

According to 9 analysts, Haemonetics (HAE) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $80.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $80.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Haemonetics (HAE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.